Captrust Financial Advisors Acquires 2,941 Shares of Encompass Health Co. (NYSE:EHC)

Captrust Financial Advisors lifted its stake in shares of Encompass Health Co. (NYSE:EHC - Free Report) by 71.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 7,065 shares of the company's stock after purchasing an additional 2,941 shares during the quarter. Captrust Financial Advisors' holdings in Encompass Health were worth $652,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Charles Schwab Investment Management Inc. grew its holdings in shares of Encompass Health by 0.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 644,764 shares of the company's stock valued at $59,544,000 after purchasing an additional 4,345 shares during the last quarter. Merit Financial Group LLC acquired a new stake in Encompass Health during the 4th quarter worth approximately $374,000. BI Asset Management Fondsmaeglerselskab A S acquired a new stake in Encompass Health during the 4th quarter worth approximately $4,160,000. MassMutual Private Wealth & Trust FSB boosted its position in Encompass Health by 87.8% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 293 shares of the company's stock worth $27,000 after buying an additional 137 shares during the period. Finally, US Bancorp DE boosted its position in Encompass Health by 9.6% during the 4th quarter. US Bancorp DE now owns 1,380 shares of the company's stock worth $127,000 after buying an additional 121 shares during the period. 97.25% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently commented on the stock. KeyCorp lifted their target price on shares of Encompass Health from $120.00 to $122.00 and gave the stock an "overweight" rating in a research report on Friday, April 25th. Wall Street Zen upgraded shares of Encompass Health from a "hold" rating to a "buy" rating in a research report on Sunday, May 11th. Barclays lifted their target price on shares of Encompass Health from $118.00 to $129.00 and gave the stock an "overweight" rating in a research report on Friday, April 25th. UBS Group lifted their target price on shares of Encompass Health from $117.00 to $130.00 and gave the stock a "buy" rating in a research report on Monday, April 28th. Finally, Royal Bank of Canada boosted their price target on shares of Encompass Health from $110.00 to $125.00 and gave the stock an "outperform" rating in a research report on Monday, April 28th. Nine research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, Encompass Health has a consensus rating of "Buy" and a consensus price target of $120.86.

Encompass Health Trading Up 0.1%

Shares of NYSE EHC traded up $0.13 during midday trading on Friday, reaching $118.74. The stock had a trading volume of 388,011 shares, compared to its average volume of 698,046. The firm has a market cap of $11.97 billion, a price-to-earnings ratio of 26.62, a price-to-earnings-growth ratio of 2.31 and a beta of 0.91. Encompass Health Co. has a twelve month low of $82.74 and a twelve month high of $121.96. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.04 and a current ratio of 1.05. The company's 50 day moving average price is $107.85 and its 200 day moving average price is $101.42.

Encompass Health (NYSE:EHC - Get Free Report) last issued its quarterly earnings results on Thursday, April 24th. The company reported $1.37 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.19 by $0.18. Encompass Health had a net margin of 8.48% and a return on equity of 17.56%. The firm had revenue of $1.46 billion for the quarter, compared to the consensus estimate of $1.43 billion. During the same quarter in the previous year, the company earned $1.12 EPS. The company's revenue for the quarter was up 10.6% on a year-over-year basis. As a group, sell-side analysts expect that Encompass Health Co. will post 4.8 EPS for the current year.

Encompass Health Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, July 15th. Investors of record on Tuesday, July 1st will be given a dividend of $0.17 per share. The ex-dividend date of this dividend is Tuesday, July 1st. This represents a $0.68 dividend on an annualized basis and a dividend yield of 0.57%. Encompass Health's payout ratio is presently 14.05%.

Insider Activity at Encompass Health

In related news, CEO Mark J. Tarr sold 118,384 shares of the business's stock in a transaction on Tuesday, May 20th. The shares were sold at an average price of $121.53, for a total transaction of $14,387,207.52. Following the transaction, the chief executive officer now owns 527,070 shares in the company, valued at $64,054,817.10. The trade was a 18.34% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP John Patrick Darby sold 10,000 shares of the business's stock in a transaction on Tuesday, April 29th. The shares were sold at an average price of $114.79, for a total transaction of $1,147,900.00. Following the transaction, the executive vice president now owns 79,710 shares in the company, valued at $9,149,910.90. The trade was a 11.15% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 132,663 shares of company stock worth $16,034,082 in the last quarter. Company insiders own 2.00% of the company's stock.

Encompass Health Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.